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Chapter 5
Epidural steroids for lumbosacral radicular 
syndrome compared to usual care: 







Klaas van der Meer





Segmental epidural steroid injections (SESIs) are a widely used additional pain 
treatment in lumbosacral radicular syndrome (LRS). Little is known about their 
effects on patients’ quality of life (QoL), their cost-effectiveness in terms of utility, 
and nothing when studied from a societal perspective or compared to other 
interventions in sciatica. This study aims to investigate the effect of adding SESIs 
to the usual care compared to usual care alone on quality of life and cost-utility in 
LRS in general practice.
Method 
We performed a pragmatic, randomized, controlled, single-blinded trial in Dutch 
general practice. Patients with acute LRS were included by GPs. All patients received 
usual care. Patients in the intervention group received one segmental epidural 
steroid injection containing 80 mg triamcinolone as well. Follow-up was performed 
using postal questionnaires at 4, 6, 13, 26 and 52 weeks, that included the SF-36 
and a specific cost questionnaire. Statistical analysis for QoL was carried out using 
mixed models. Economic evaluation was performed from a societal perspective 
with a time horizon of one year. SF-36 scores were transformed to utility scores by 
using the SF-6D profiling method described by Brazier et al.
Results
Both groups experienced significant increase in quality of life in (especially) the 
physical domains of the SF-36. The intervention group scored significantly better 
than the control group at certain time points in the physical domain. The differences 
were small. The cost-utility analysis showed that with a negligible loss of utility 
societal costs would be saved, due to more productivity in the intervention group.
 
Conclusion
Although the beneficial effects of SESIs are small and the natural course of LRS is 
predominantly favourable, we think decision makers can consider implementing 
SESIs in daily practice with the purpose of saving resources. Caution must be taken, 
and further research should be directed at identifying patient subgroups who might 
benefit from SESIs, with additional focus on (costs of) complications and side 
effects.
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INTRODUCTION
Lumbosacral radicular syndrome (LRS) is pain, radiating from the back to below 
the knee in one leg (“sciatica”), with a positive straight leg raising test and/or 
neurological symptoms originating from one nerve root.1 It is most commonly 
caused by lumbar disc herniation, resulting in an inflammatory response around 
the nerve root that causes radicular pain. Sciatica is pain of a burning or shooting 
nature and has a high impact on patients’ general wellbeing due to its intensity.2 
Segmental epidural steroid injections (SESIs), that may inhibit the inflammatory 
response around the nerve root, are a controversial treatment in LRS.3,4 They are 
found to be effective in treating pain on the short term, in the acute phase of well-
defined radicular syndrome with sciatica, causing few side-effects.5,6-15 SESIs are 
applied in LRS in The Netherlands but they are not advised in the national guideline 
as a routine treatment.1 Low back pain and sciatica are expensive as well in terms of 
health care costs: medical costs of low-back pain amounted to 337,3 million euros 
in the Netherlands in 2000.16 
 In a pragmatic randomized controlled trial, we compared the effectiveness of 
adding a segmental epidural steroid injection to the usual care of LRS to usual care 
alone. We found a small significant difference in favour of the intervention for back 
pain, impairment, disability and patients’ satisfaction with treatment.17 A cost-
effectiveness analysis showed that adding the intervention to the usual care was 
considerably cheaper than usual care alone, mainly due to more loss of productivity 
in the control group.18
 Given an intervention’s clinical superiority or equivalence, lower costs are an 
important economic argument to have it implemented. Its effect on patients’ quality 
of life has to be taken into account. Next, decision makers need to be able to compare 
different interventions to weigh their costs and benefits. Although SESIs are a 
widely used additional pain treatment in LRS, little is known about their effects on 
patients’ quality of life, their cost-effectiveness in terms of utility, and nothing when 
studied from a societal perspective or compared to other interventions in sciatica. 
We therefore compared health-related quality of life in patients with acute LRS who 
received usual care with patients who received usual care with an additional SESI. 
We also carried out a cost-utility analysis assessing the balance between QALYs 




Overall, 63 patients aged 18-65 years, in the acute phase of LRS, participated in a 
pragmatic randomized controlled trial comparing usual care to a SESI combined 
with usual care. Inclusion took place in 2005 to 2007. Patients were followed for 
one year. Exclusion criteria were a history of spinal surgery or trauma, maintenance 
therapy with corticosteroids or anticoagulants, bleeding disorder, cauda equina 
syndrome, a BMI > 35, mental disability, inadequate mastery of the Dutch language, 
allergy to corticosteroids, pregnancy or an active wish to conceive and breastfeeding. 
The study was reviewed and approved by the institutional medical-ethical board of 
the University Medical Centre Groningen.
 Patients who contacted their GP for LRS were given written information on 
the study, a baseline questionnaire and an informed consent form. The forms were 
completed and sent to the research center. Upon receiving the baseline questionnaire 
and the informed consent, the primary researcher contacted the subjects to check 
inclusion and exclusion criteria. Randomization was performed by an otherwise 
non-involved colleague, using pre-prepared, sequentially numbered, opaque, 
sealed envelopes containing stickers with either “SESI” or “CAU”, balanced after 40 
assignments. Upon randomization, the due envelope was opened and the sticker 
with the allocated treatment was fixed on the completed inclusion form. Inclusion 
forms were coded and kept separately from coded follow-up questionnaires. 
Researchers were blinded until after the final analysis of the results. 
 As demanded by the pragmatic study design, usual daily practice circumstances 
were closely followed. All patients received care as usual according to the guideline 
(analgesics, maintaining normal daily activities as much as possible, referral if 
necessary) from their GPs. Patients in the intervention group received a SESI in 
addition to usual care. SESIs consisted of 80 mg triamcinolone in normal saline and 
were administered at the department of anesthesiology pain management center of 
the university medical hospital Groningen (UMCG). Both groups were followed 
with questionnaires regarding pain, disability, health-related quality of life and 
costs. Measuring instruments used were numerical rating scales (NRS) for pain, 
the Roland-Morris disability questionnaire for disability, the SF-36 questionnaire 
for quality of life and specifically developed cost questionnaires for costs. The NRS 
score for back pain at four weeks after the start of the treatment was used as the 
primary outcome measure for calculating sample size. We needed to include 33 
subjects in each group to detect a difference of 1.2 and a common within-group 
standard deviation of 1.7, as is reported in literature as minimal clinically important 
difference in back pain (β = 0.80, α = 0.05 two-tailed).19,20 
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Quality of life
Quality of life was measured using the SF-36 health related quality of life questionnaire 
at baseline and at 4, 13, 26 and 52 weeks after the start of the treatment.21 Physical 
and mental component scores were calculated using an uncorrelated (orthogonal) 
factor solution.22 Analysis was carried out on an intention to treat basis, using 
mixed models. In this type of regression analysis, the mean outcomes in our study 
population (which provide an approximation of the mean values in the general 
population), were used to estimate the means in the general population. Therefore 
estimated means, rather than measured values, are presented. Patients were a 
random factor in the model with variance components as covariance structure, 
treatment a fixed factor. Time of measurement was as a categorical variable entered 
in the model. For every outcome variable, treatment and time of measurement as 
independent variables were tested with sex, age and baseline-values as covariates to 
account for non-balance in the randomization. 
Cost-utility
The aim of cost-utility analyses is to estimate the ratio between the cost (or 
savings) of an intervention and the benefit it produces in terms of years lived in full 
health (Quality Adjusted Life Years, QALYs). Cost-utility analyses therefore allow 
comparison across different health programs and policies by using a common unit 
of measure (money/QALYs) which is why cost-utility analyses are used to guide 
procurement decisions. Our cost utility analysis compared societal costs per QALYs 
at one year between the intervention group and the usual care group. Since the SF-
36 is not a preference-based questionnaire, the scores were transformed to utility 
scores using the SF-6D profiling as described by Brazier et al.23 The SF-6D includes 
the following health domains: physical functioning, role participation (combined 
role-physical and role-emotional), social functioning, bodily pain, mental health 
and vitality. Areas under the curves were calculated for each patient using the 
standard trapezoidal method which is based on the following formula:
AUC1 = Yi,0 + Yi,1 * (t1-t0) + Yi,1 + Yi,2 * (t2-t1)+ Yi,2 + Yi,3 * (t3-t2) + Yi,3 + Yi,4 * (t4-t3)                      
       2         2           2             2
where Yx is the utility weight for a given time point and t is the time point expressed 
in weeks after inclusion. 
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 The economic evaluation was performed with a time horizon of one year from 
a societal perspective, which means that all direct medical, and all direct and 
indirect non-medical costs including loss of productivity, were taken into account 
regardless of who pays for them. Unit prices were drawn from the guidelines for 
cost-studies (methods and unit-prices for economic evaluations in health care) and 
online information on medication costs by the Dutch health insurance board.24,25 
The cost utility analysis was performed with as main outcome the Incremental 
Cost Utility Ratio (ICUR). Differences between groups over the entire study period 
were calculated with 95% confidence intervals based on bootstrap resampling with 
5000 replications. The bootstrapped confidence interval was calculated by taking 
the 2.5th and 97.5th percentile of the rank ordered scores. The simulated values of 
the cost and QALY estimates were plotted in a cost effectiveness plane. Finally, a 
cost effectiveness acceptability curve was generated, depicting the probability that 
adding SESIs to usual care is cost-effective over a range of thresholds. 
RESULTS
Population
Our patients were recruited from the urbanized countryside in the northern part of 
the Netherlands. A flow schedule is presented in figure 5.1. Of 84 patients presented 
to us by 24 GPs, 73 were randomized and 50 subjects included in the final analysis 
for quality of life. Of six people only the direct medical costs were known, and since 
we needed a complete ‘cost-effect pair’ to calculate societal costs per QALY, these 
had to be excluded, resulting in 22 subjects per group. The mean age of the study 
participants at the time of the inclusion was 44,3 years (SD 9,5). 
Quality of life
In table 5.1, all measured baseline values of both groups for all domains of the 
SF-36 are presented. In table 5.2, we present all estimated group means stratified 
by study arm, and the estimated differences between group means for every 
measuring moment, including 95% confidence intervals. The group means were 
significantly different (i.e. the confidence interval did not include zero) in favor 
of the intervention at some time points for the domains of physical functioning, 
physical role limitations, general health perceptions and the physical component 
summary. The largest differences between group means were found in the domain 
of physical role limitations: -33.7 [95% CI -54.8, -12.7] and -29.1 [95% CI -50.9, 
-7.4] after a follow-up time of half a year and a year respectively.
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 Presented by GP
(n = 84)
Excluded (n = 11)
Not meeting inclusion 
criteria (n = 7)










Lost to follow-up (n=12):
3 subjects ended their 
participation.
1 subject died during the 
study period.
8 subjects did not 
adequately complete the 
SF-36
Included in Mixed 
Models analysis 
for quality of life 
(n = 25)
Included in Mixed 
Models analysis 
for quality of life 
(n = 25)
Lost to follow-up (n=11):
4 subjects ended their 
participation. 
7 subjects did not 









effect pair (n = 3)
Incomplete cost-
effect pair (n = 3)
Figure 5.1: Population flow schedule
Table 5.1: Baseline participant characteristics for quality of life
Group Intervention group (n = 25) Control group (n = 25)
Physical functioning 53 (17) 61 (22)
Social functioning 48 (15) 44 (19)
Role limitations, physical 14 (29) 23 (38)
Role limitations, emotional 70 (43) 70 (43)
Emotional wellbeing 65 (27) 66 (20)
Energy/fatigue 52 (24) 51 (17)
Pain 45 (17) 45 (16)
General health perception 70 (18) 67 (16)
Change in perceived health 40 (21) 40 (21)
Physical component score 45 (11) 49 (15)
Mental component score 58 (20) 58 (17)
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Table 5.2: Estimated mean SF-36 scores
Variable Week 4 Week 12 Week 26 Week 52
Physical 
functioning
SESI 74.8 (69.2, 80.5) 87.7 (82.1, 93.4) 91.9 (86.2, 97.6) 94.5 (88.7, 100.3)
UC 73.9 (68.4, 79.3) 79.0 (73.2, 84.7) 82.5 (76.7, 88.3) 87.0 (81.1, 93.0)
Difference -0.97 (-8.9, 6.9) -8.8 (-16.9, -0.7) -9.4 (-17.6, -1.2) -7.5 (-15.9, 0.9)
Social 
functioning
SESI 48.1 (42.4, 53.8) 48.9 (43.1, 54.6) 53.4 (47.7, 59.1) 51.7 (45.9, 57.6)
UC 45.4 (39.8, 50.9) 44.5 (38.8, 50.2) 50.0 (44.1, 55.7) 47.1 (41.2, 53.0)
Difference -2.7 (-10.7, 5.2) -4.3 (-12.5, 3.8) -3.5 (-11.6, 4.7) -4.6 (-13.0, 3.7)
Physical role 
limitations
SESI 29.0 (14.4, 43.6) 59.7 (45.3, 74.1) 87.2 (72.6, 102.0) 92.3 (77.4, 107.2)
UC 26.2 (12.3, 40.2) 45.7 (30.8, 60.6) 53.3 (38.6, 68.5) 63.2 (47.5, 79.0)




SESI 78.5 (66.7, 90.4) 87.5 (75.7, 99.4) 93.5 (81.5, 105.6) 94.3 (82.1, 106.6)
UC 66.8 (55.3, 78.2) 74.0 (61.7, 86.2) 79.5 (67.0, 92.0) 85.2 (72.6, 98.0)
Difference -11.7 (-28.3, 4.8) -13.6 (-30.7, 3.5) -14.0 (-31.4, 3.3) -9.1 (-26.7, 8.6)
Emotional 
wellbeing
SESI 69.8 (63.7, 75.9) 69.8 (63.8, 75.8) 67.6 (61.6, 73.6) 67.4 (61.3, 73.6)
UC 64.9 (59.1, 70.7) 71.0 (64.9, 77.1) 67.2 (61.0, 73.4) 72.2 (65.9, 78.5)
Difference -4.9 (-13.4, 3.5) 1.2 (-7.3, 9.8) 0.4 (-9.0, 8.2) 4.7 (-4.1, 13.5)
Energy/
fatigue
SESI 49.0 (43.3, 55.3) 54.3 (50.5, 62.9) 56.9 (53.2, 65.9) 55.6 (50.5, 63.4)
UC 49.3 (43.8, 56.1) 56.7 (48.2, 60.5) 59.6 (50.7, 63.1) 57.0 (49.3, 62.0)
Difference -0.6 (-9.2, 7.9) 2.4 (-6.4, 11.1) 2.7 (-6.1, 11.5) 1.4 (-7.7, 10.4)
Pain SESI 52.4 (48.5, 56.3) 51.5 (47.6, 55.3) 49.6 (45.8, 53.4) 49.7 (45.8, 53.6)
UC 47.6 (43.9, 51.3) 48.4 (44.5, 52.2) 48.8 (44.9, 52.7) 51.2 (47.2, 55.2)




SESI 74.0 (68.6, 79.6) 73.5 (67.9, 79.0) 77.1 (71.5, 82.6) 78.2 (72.4, 83.9)
UC 66.0 (60.6, 71.4) 66.7 (61.1, 72.4) 70.2 (64.5, 76.0) 73.5 (67.6, 79.3)




SESI 45.2 (35.2, 55.2) 57.9 (47.9, 67.9) 68.6 (58.6, 78.6) 87.8 (77.5, 98.1)
UC 45.5 (35.8, 55.2) 55.3 (45.1, 65.4) 64.0 (53.6, 74.3) 73.3 (62.8, 83.8)




SESI 58.2 (52.8, 63.5) 68.9 (63.6, 74.2) 77.7 (72.3, 83.0) 79.5 (74.4, 85.0)
UC 53.3 (48.1, 58.4) 59.4 (54.0, 64.9) 63.1 (57.6,  68.5) 67.6 (61.9, 73.4)




SESI 61.8 (57.0, 66.6) 65.0 (60.3, 70.0) 67.3 (62.4, 72.1) 67.0 (62.1, 71.9)
UC 56.4 (51.8, 61.0) 61.2 (56.3, 66.2) 64.1 (59.1, 69.1) 65.2 (60.1, 70.3)
Difference -5.4 (-12.0, 1.2) -3.8 (-10.6, 3.1) -3.2 (-10.1, 3.8) -1.9 (-8.9, 5.2)
In this table, all mean scores with standard deviations of the intervention group and the control group 
for all domains of the SF-36 questionnaire at all measuring moments including the difference between 
groups with 95% confidence intervals are presented. The score range of the SF-36 is 0-100, with higher 
scores indicating better quality of life. The measured values of our study population were used to 
estimate the values in the general population.
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Over time, when calculated for the entire follow-up period as a whole, both groups 
experienced a significant decline of symptoms for physical functioning (p < 0.0001 
in both groups), physical role limitations (p = 0.0001 in the intervention group, p < 
0.0001 in the control group), emotional role limitations (p = 0.03 in the intervention 
group, p = 0.01 in the control group), change in perceived health (p < 0.0001 in both 
groups) and the physical component score (p < 0.0001 in both groups). The control 
group experienced a significant decline of symptoms for emotional wellbeing (p 
= 0.03), energy/fatigue (p = 0.04), general health perception (p = 0.03) and the 
mental component score (p = 0.003) but the intervention group did not. For social 
functioning, neither group experienced a significant decline of symptoms. 
 When groups were compared, the intervention group experienced significantly 
less symptoms for physical functioning (p = 0.03), physical role limitations (p = 
0.006), emotional role limitations (p = 0.04), general health perceptions (p = 0.02) 
and the physical component score (p = 0.0002) than the control group. Interactions 
between groups were not significant for any of the SF-36 domains when calculated 
over the follow-up period as a whole.
Cost-utility
The difference in utility between the intervention group and the control group was 
0.0084 QALYs in favor of the control group. This equals a loss of three days in perfect 
health in the intervention group. Societal costs were higher in the control group 
than the intervention group, which resulted in a mean cost difference of €1,626 
[-€2,133 to €5,384 95% CI] between groups over the course of one year, mainly due 
to loss of productivity. The ICUR, (point estimate for costs saved per QALY lost) 
was €193,354 [-€859,133 to €2,352,223 95% CI]. Figure 5.2 shows the results of the 
bootstrap simulations of cost-QALY pairs. The majority of estimates were located 
in the south-western quadrant (78%) indicating less QALYs at lower costs (costs 
saved per QALY lost). Figure 5.3 shows the cost-effectiveness acceptability curve 
(CEAC). The probability that adding SESIs to standard care is cost-effective starts at 
80% with a threshold of  €0. This implies that, (compared to usual care), the chance 
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Figure 5.2: Bootstrapped costs and utility.
The majority of estimates (78%) were located in the south-western quadrant indicating less QALYs at 
lower costs (costs saved per QALY lost). Another 19% of cost-utility pairs were in the north-western 
quadrant (less utility at higher costs) and a negligible amount of estimates were in the eastern part 

























Value of ceiling ratio 
Figure 5.3: Cost-effectiveness acceptability curve 
The CEAC graphically shows the probability of whether it would be cost-effective in terms of utility 
to add SESIs to care as usual, compared to care as usual alone, at a specific ceiling ratio. This means 
that the probability that a certain intervention is considered cost-effective rises with the willingness of 
decision makers to invest in this intervention. In the current situation, without additional investment, 
the probability that SESIs as an additional treatment are cost-effective is already 80% (the starting 
point of the curve). 




Both our study groups experienced significant increase in quality of life, in 
(especially) the physical domains of the SF-36, with the intervention group scoring 
significantly better than the control group at certain time points. In terms of utility, 
implementing SESIs as an additional pain treatment for LRS in general practice 
would lead to a negligible loss of QALYs. These seemingly paradoxical outcomes 
are probably explained by the manners in which they are generated: quality of life, 
derived from the SF-36 questionnaire, is a patient-based outcome whereas utility, 
derived from the SF-6D, is a preference-based outcome.23 The cost-utility analysis 
showed that with a minimal loss of utility, societal costs would be saved, due to 
more productivity in the intervention group. 
Strengths and limitations
To our knowledge, this study is the first to evaluate the influence of adding SESIs 
to the treatment of acute LRS on quality of life and cost-utility from a societal 
perspective. Furthermore, our study was undertaken entirely in general practice, 
where the majority of patients with LRS are cared for, unlike most other research 
which is performed in a hospital setting. This study also has some possible 
limitations. The SF-36 cannot be used directly to measure utility since it is not 
preference based. A meaningful health state classification (the SF-6D) can be created 
from the SF-36 by applying the score transformation as described in the method 
section.23 Direct measures of utility, for example the EuroQoL questionnaire, may 
have more construct responsiveness and validity in chronic pain.28 However, to our 
knowledge, no comparison between the two questionnaires in acute pain is made 
as yet, and in some other disease areas the SF-6D was found superior.29 Moreover, 
the SF-6D is also used by other authors performing cost-utility analyses in patients 
with sciatica.6,26,30. We therefore feel that the use of an indirect measure of utility 
was justified. Another limitation is the relatively large number of dropouts due to 
unsatisfactorily completion of the SF-36 questionnaires. We probably overloaded 
our study subjects. Our selections of 50 and 44 subjects did not differ in age or 




 Differences in utility between all kinds of interventions for sciatica are small. 
Differences in societal costs vary. From our study results, we learned that a societal 
costs can be saved against a negligible loss of utility by implementing SESIs as an 
additional pain treatment in LRS. It seems a logical choice for decision makers 
to implement an intervention that is not inferior to the usual treatment and less 
expensive to society. However, SESIs are invasive procedures with risks of both 
local complications and systemic side-effects.5,31,32 The beneficial effects of SESIs 
in terms of pain, disability and quality of life are small and the natural course of 
LRS is predominantly favourable. We therefore conclude that decision makers can 
consider implementing SESIs in daily practice with the purpose of saving resources, 
provided that caution is taken. Further research should be aimed at identifying 
patient subgroups that might benefit the most from SESIs, with additional focus on 
(costs of) complications and side effects.
Other research
The WEST-study is a hospital-situated, multi-centre, pragmatic RCT in which 
quality of life and utilities were measured using the SF-36 and SF-6D. The researchers 
found a significant improvement in quality of life in both the SESI and the placebo 
group over time (p<0.001 after both 13 and 52 weeks).6 They did not, however, find 
any significant difference in quality of life between groups. The incremental QALY 
gained provided by their cost-utility analysis was 0.0059 which is equivalent to an 
additional 2.2 days of full health. The incremental costs were £152 from a provider 
perspective (costs to the provider based on real resource use) and £992 from a 
purchaser perspective (prices charged to purchasers based on total costs of service 
including overheads). The costs found per QALY gained were therefore £25,746 
from a provider perspective and £167,145 from a purchaser perspective. The results 
of the cost-utility analyses are in this case difficult to compare to ours since we have 
used a societal perspective (all costs are measured regardless of who pays for them). 
In our study, the majority of costs are saved in the field of productivity loss, which is 
not taken into account using a purchaser’s or provider’s perspective.
 As stated in the introduction section, cost-utility analyses enable comparison 
between different health care interventions by using a single unit of measure 
(QALYs). In sciatica, the cost-effectiveness in terms of utility of other interventions 
has been studied. In a cost-utility analysis alongside a randomized controlled trial 
comparing prolonged conservative care with early surgery in patients with sciatica, 
researchers found incremental QALYs in favour of early surgery of 0.044 (0.005 – 
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0.83) using the UK EQ-5D, 0.032 (0.005 – 0.059) using the US EQ-5D and 0.024 
(0.003 – 0.046) using the SF-6D.24 They found a negligible difference in total societal 
costs of €12 (-€4,029 - €4,006) in favour of early surgery. In this case, the higher 
healthcare costs of early surgery balanced out against its lower costs in productivity 
loss. This amounts to costs per QALY gained of €273, €375 and €500 respectively. 
Another cost-utility analysis alongside a randomized controlled trial compared 
the differences between tubular discectomy and conventional microdiscectomy 
in the treatment of sciatica.25 They found non-significant incremental QALYs in 
favour of conventional microdiscectomy of -0.012 (-0.046 – 0.021), -0.014 (-0.056 
– 0.029) and -0.11 (-0.037 – 0.014) with the US EQ-5D, the UK EQ-5D and the 
SF-6D respectively. The difference in incremental societal costs was $1032 (-$1,494 
- $3,557), also in favour of conventional microdiscectomy (€826 (-€1,196 - €2,847)). 
This amounts to savings per QALY of $86,000, $73,714 and $9,382 respectively 
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